PatternsRadar
Sign in

PPLPHARMAPiramal Pharma Limited

NSE
Full chart
200.52INR+5.63 (+2.89%)Close · 6 Oct 2026
29 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹26,696 CrMarket cap
—P/E (TTM)
37.0%Delivery

Filings & corporate actions

16 results filed
CSV
Next results · Q2 FY27
Expected 23 Oct 2026 – 10 Nov 2026
Estimate: filed 23–41 days after quarter end, last 4 times
Dividend
₹0.14 per share · last 16 Jul 2025
2026
  • 29 JulresultsResults · Q1 FY27 · consolidated and standalone+0.5%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026-0.3%NSE
  • 28 AprresultsResults · Q4 FY26 · consolidated and standalone-2.6%NSE
  • 20 AprshareholdingShareholding · 31 Mar 20260.0%NSE
  • 29 JanresultsResults · Q3 FY26 · consolidated and standalone-0.2%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-4.0%NSE

Reaction to results · all yearsrose on day 0 in 9 of 16 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2729 Jul 2026+0.5%+6.4%+9.8%2.7×
Q4 FY2628 Apr 2026-2.6%+11.7%+5.1%1.0×
Q3 FY2629 Jan 2026-0.2%+5.3%+4.6%5.7×
Q2 FY265 Nov 2025-0.5%-3.3%-9.8%4.8×
Q1 FY2628 Jul 2025+0.6%-5.3%-8.8%2.9×
Q4 FY2514 May 2025-4.8%-5.8%-8.7%4.1×
Q3 FY2528 Jan 2025+9.5%+3.9%-3.6%2.8×
Q2 FY2523 Oct 2024+17.4%+23.2%+14.8%13.2×
Q1 FY2526 Jul 2024+0.1%+4.8%+12.6%6.0×
Q4 FY2410 May 2024+2.5%-0.6%+4.5%9.3×
Q3 FY2430 Jan 2024+3.8%+0.3%-6.3%3.0×
Q2 FY2428 Oct 2023+3.2%+17.3%+31.9%6.9×
Q1 FY243 Aug 2023-2.4%-7.1%-1.2%0.8×
Q4 FY2325 May 2023+5.2%+4.4%+15.5%3.4×
Q3 FY239 Feb 2023-9.9%-7.9%-27.2%5.7×
Q2 FY2310 Nov 2022-1.6%-4.8%-7.8%—
Average+1.3%+2.6%+1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+17.4%
Profit YoY—
Interest cost YoY-14.5%
Revenue QoQ-17.5%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+4.8%+7.8%————
Profit——————

Key data

CSV
Open195.48
Day range193.75 – 201.20
52-week range132.30 – 231.93
From 52w high-13.5%
RSI (14)43.6
ATR (14)7.28
Volume17.19L
Avg volume (20D)41.76L
Rel volume0.41×
Volatility (1Y)33.9%
Turnover₹34.5Cr
SMA 50 / 200208.45 / 174.54

Delivery percentage

Latest · 6 Oct 202637.0%
20-day avg41.0%
1-year avg38.3%
Percentile (own history)29th
Range5.8–100.0%
Sessions982

Over the last 20 sessions PPLPHARMA settled 41.0% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 38.3%, so recent sessions are running 2.8 points higher than usual. The latest session ranks higher than 29% of the 982 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+2.89%-2.94%-6.51%+14.43%+41.03%+6.81%

Valuation

CSV
Market cap₹26,696 Cr
P/E (TTM)—
EPS (TTM)-2.36
Shares outstanding132.74Cr
Listed19 Oct 2022

Ownership

CSV
Promoter34.80%
Promoter Δ QoQ-0.06 pp
Public64.72%
FII12.52%
DII14.57%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)2,043.72,139.92,751.82,269.9
YoY chg-8.8%-2.9%-0.1%+17.4%
Net profit (₹ Cr)(99.2)(136.2)(8.8)(69.4)
YoY chg-539.2%-3800.8%-105.7%—
Net margin-4.9%-6.4%-0.3%-3.1%
EPS-0.75-1.03-0.07-0.52

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 34.80% · public 64.72%
18 Oct 2022: promoter 34.79%31 Dec 2022: promoter 34.79%31 Mar 2023: promoter 34.79%30 Jun 2023: promoter 34.79%22 Aug 2023: promoter 35.02%27 Sept 2023: promoter 35.02%30 Sept 2023: promoter 35.02%31 Dec 2023: promoter 35.02%31 Mar 2024: promoter 35.02%30 Jun 2024: promoter 34.95%30 Sept 2024: promoter 34.95%31 Dec 2024: promoter 34.95%31 Mar 2025: promoter 34.95%30 Jun 2025: promoter 34.86%30 Sept 2025: promoter 34.86%31 Dec 2025: promoter 34.86%31 Mar 2026: promoter 34.86%30 Jun 2026: promoter 34.80%
2022-102026-06
  • Promoter
  • Public and others
Promoter
34.80%
Public
64.72%
Promoter change
-0.06 pp
Filed
20 Jul 2026
FII
12.52%
DII
14.57%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue from operations1,911.41,958.62,552.41,951.12,241.82,204.22,754.11,933.72,043.72,139.92,751.82,269.9
Other income49.261.526.419.561.112.142.058.465.643.246.189.4
Total income1,960.62,020.12,578.71,970.72,302.92,216.42,796.11,992.12,109.32,183.12,797.82,359.3
Total expenses1,940.11,982.42,332.82,038.22,200.02,166.62,539.52,110.42,170.32,246.12,592.62,386.4
└ Finance costs109.9105.9114.2107.0107.6103.3103.786.282.489.283.088.1
└ Depreciation184.5186.3196.1184.6192.2196.8242.8197.3202.8212.7218.4223.6
Profit before tax20.55.4215.4(67.5)102.949.8256.6(97.6)(61.0)(104.1)29.4(27.0)
Tax expense34.59.3126.243.697.563.1119.32.753.042.351.861.9
Net profit5.010.1101.3(88.6)22.63.7153.5(81.7)(99.2)(136.2)(8.8)(69.4)
EPS0.040.080.77-0.670.170.031.16-0.62-0.75-1.03-0.07-0.52
Net margin0.26%0.52%3.97%-4.54%1.01%0.17%5.57%-4.23%-4.85%-6.36%-0.32%-3.06%
PBT margin1.07%0.28%8.44%-3.46%4.59%2.26%9.32%-5.05%-2.98%-4.87%1.07%-1.19%
Tax rate168.90%170.98%58.58%—94.82%126.87%46.50%———176.11%—

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 29 Jul 2026.

PPLPHARMA at a glance

  • PPLPHARMA closed at ₹200.52 on 6 Oct 2026, +2.89% on the day, +6.8% over one year, 13.5% below its 52-week high of ₹231.93.
  • Delivery was 37.0% of traded quantity on 6 Oct 2026, the 29th percentile of its own 982 sessions with a reading (20-session average 41.0%, 1-year average 38.3%).
  • Market capitalisation is ₹26,696 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-2.36).
  • Q1 FY27 results (consolidated, filed 29 Jul 2026): revenue ₹2,270 crore (+17.4% year on year), net profit ₹-69 crore; the price moved +0.5% on the first session after.
  • Promoters held 34.80% at 30 Jun 2026, down 0.06 percentage points on the previous filing.
  • Q2 FY27 results are expected between 23 Oct 2026 and 10 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE0DK501011
SeriesEQ
Listed19 Oct 2022
History from19 Oct 2022
Sessions983
Turnover rank#326

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE